Pharmanutra
Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 33 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1,192,014 kg CO2e. This figure includes 229,189 kg CO2e from Scope 1 emissions, 270,515 kg CO2e from Scope 2 emissions (market-based), and significant Scope 3 emissions of 751,110 kg CO2e, which comprise 684,328 kg CO2e from business travel and 86,782 kg CO2e from employee commuting. Comparatively, in 2022, the company recorded total emissions of about 199,150 kg CO2e for Scope 1 and 57,666 kg CO2e for Scope 2 (market-based), with no reported Scope 3 emissions. This indicates a substantial increase in emissions in 2023, particularly in Scope 3 categories, highlighting the importance of addressing indirect emissions in their climate strategy. Pharmanutra has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of formal reduction targets suggests a need for enhanced climate action strategies within the organisation. The emissions data is not cascaded from any parent company, indicating that Pharmanutra S.p.A. independently reports its emissions and climate commitments. As the company continues to grow, addressing its carbon footprint will be crucial for aligning with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 39.72 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | - | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanutra is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
